Research done by groups at National Cancer Institut has shown that RADIL can regulate neutrophil adhesion and chemotaxis by RADIL-mediated integrin and focal adhesion kinase (FAK) activation (20), which has been reported as a potentially important new target for cancer therapy (21). The gene discussed is PTK2; the disease is cancer.